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The development and mass-production of 
antibiotics ranks as one of the twentieth cen-
tury’s greatest scientific achievements. For 
more than 60 years, antibiotics have com-
prised Western medicine’s primary defense 
against bacterial disease. But although 
antibiotics have saved millions of lives, our 
chemical shield has become increasingly 
leaky. Just last year, the director-general of 
the World Health Organization warned that 
“the world is on the brink of losing these 
miracle cures [antibiotics]” and that “in 
the absence of urgent corrective and pro-
tective actions, the world is heading toward 
a post-antibiotic era, in which many com-
mon infections will no longer have a cure 
and, once again, kill unabated” (Liljeqvist 
et al., 2012).
Unfortunately, game-changing help 
from new antibiotics does not appear to 
be forthcoming. Over the past 30 years, the 
number of antibiotics newly approved in 
the United States has steadily declined, and 
despite increased awareness and redou-
bled efforts, the current R&D pipeline 
remains largely dry (Hughes, 2011). Even 
when effective antibiotics are available, it is 
becoming increasingly apparent that broad-
spectrum antibiotics can have sustained and 
detrimental effects on the body’s commu-
nities of beneficial bacteria (Buffie et al., 
2011) which, according to a growing body 
of research, play a vital role in human nutri-
tion (Yan and Polk, 2004) and immunity 
(O’Hara and Shanahan, 2006).
Given the underlying economic factors 
that make antibiotic development unprof-
itable, (Nathan and Goldberg, 2005) and 
given that abuses of antibiotics continue to 
drive bacterial resistance, it seems unreal-
istic to assume that antibiotics alone will 
prove sufficient to counter the long-term 
medical threat posed by drug-resistant 
bacteria. Rather than continuing to focus 
solely on chemical solutions to drug-resist-
ance, which are ultimately static responses 
d’Herelle’s expertise, and largely because of 
a poor understanding of basic phage biol-
ogy, early returns from phage therapy were 
mixed. In 1932, one American health officer 
presciently warned, “Because of conflicting 
experimental observations, enthusiastic and 
poorly controlled clinical application and 
rapidly expanding commercial exploitation, 
a situation is developing which will, unless 
guided and checked, lead to the ultimate 
rejection of bacteriophage by all who make 
any pretense to the practice of scientific 
medicine” (Larckum, 1932).
This rejection of phage therapy, which 
began with the misuse of phages, became 
complete with the emergence of antibiot-
ics. Initially, antibiotics were cheap, widely 
available, and extremely effective against 
nearly all bacterial diseases, and because 
this golden age of antibiotic infallibility 
seemed like medicine’s new status quo, 
phage therapy was discarded throughout 
the West as an unnecessary approach to an 
already-solved problem.
As has become uncomfortably apparent, 
though, bacterial diseases are not a solved 
problem, and scientists are now looking 
back to phages as a way to treat the most 
intractable bacterial infections. In the pro-
cess, it has become clear that phage therapy 
holds some important advantages over 
traditional chemotherapy. Most impor-
tantly, phages are extremely precise: any 
given phage only attacks a very particular 
strain of bacteria. In d’Herelle’s time, this 
fact often confounded, rather than aided, 
effective treatment, but today, advances in 
diagnostic technologies, such as real-time 
PCR (Espy et al., 2006), 16s rRNA sequenc-
ing (Rhoads et al., 2012), and laser-induced 
breakdown spectroscopy (Mohaidat et al., 
2012), seem likely to greatly facilitate the 
rapid selection of appropriate phages. From 
a therapeutic perspective, this means that 
phage therapy can eliminate an individual 
patient’s infection without affecting the 
to a dynamic system, we must also seek 
approaches that can keep pace with the bac-
teria they are designed to kill. This idea is 
not futuristic or even theoretical: we can tap 
into an ancient arms race between bacteria 
and their viral predators, bacteriophages, 
to combat drug-resistant bacteria. Phage 
therapy, or the use of bacteriophages to kill 
pathogenic bacteria, represents a potentially 
significant, if currently underdeveloped, 
weapon in our ongoing battle against bac-
terial disease.
The purpose of this piece is not to pro-
vide a comprehensive history of phage 
therapy, but in order to understand its 
future prospects in Western medicine, some 
basic history is helpful. Bacteriophages, or 
“bacteria eaters” in Latin, were indepen-
dently discovered by two microbiologists, 
Frederick Twort and Felix d’Herelle, in 
the late 1910s (Lederberg, 1996). Almost 
immediately, d’Herelle understood that 
these natural antagonists of bacteria repre-
sented a powerful new way of treating bacte-
rial infections. The breakthrough came in 
1919, when d’Herelle used phages to cure 
four patients of dysentery, and from there, 
phage therapy, when conducted by knowl-
edgeable scientists like d’Herelle, met with 
significant success. D’Herelle used phages 
to halt outbreaks of cholera in India and 
plague in Egypt, and in 1923, two physi-
cians from Baylor University’s College 
of Medicine, reporting successful results 
from one of the first phage therapy trials 
conducted in the United States, concluded 
that “the bacteriophage holds enormous 
possibilities as a new weapon for fighting 
infectious disease” (Ho, 2001).
Despite (or perhaps because of) the 
heady enthusiasm for phage therapy, clini-
cal results often failed to match the hype. 
Although phage products soon became 
commercially available in the United States, 
Western Europe, and the nascent Soviet 
Union, not every practitioner possessed 
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as a multivalent cocktail) are carefully 
selected to treat a patient’s specific bacte-
rial infection. Success rates from these cus-
tomized phages are five- to sixfold higher 
than that of standardized phage products 
(Zhukov-Verezhnikov et al., 1978), so the 
use of personalized phage cocktails has 
historically been crucial for effective treat-
ment. Nonetheless, the U.S. Food and Drug 
Administration (FDA), which will decide 
the fate of phage therapy in the United 
States and influence its adoption around 
the world, has not been receptive to this 
idea. To date, the FDA has essentially grafted 
its traditional antibiotic regulatory proto-
cols onto phage therapy, meaning that all 
components of a phage cocktail must go 
through individual clinical trials and that 
the composition of these cocktails cannot be 
altered without re-approval (Thiel, 2004). 
This policy does not reflect the fundamental 
differences between phages and antibiotics, 
and would, if perpetuated, likely render 
phage therapy both prohibitively expensive 
and significantly less effective.
Fortunately, there exists at least one 
regulatory precedent that could be appro-
priately applied to phage therapy: rather 
than regulate phage cocktails as it does drug 
cocktails, the FDA could instead regulate 
phage cocktails in a manner analogous to 
the FluMist® influenza vaccine. Each year, 
FluMist®, a live-virus vaccine compris-
ing a cocktail of three or four attenuated 
influenza strains, is reformulated to most 
effectively counter circulating flu strains 
(Marwick, 2000). Rather than mandate 
separate clinical trials for each season’s vac-
cine, the FDA has instead approved the pro-
cess by which FluMist® is developed. Such a 
regulatory model could also be applied to 
phage cocktails: rather than requiring sepa-
rate trials for each component of a prepara-
tion, the FDA could instead set stringent 
guidelines on the process by which those 
cocktails are produced. For instance, the 
FDA could establish formal standards for 
the screening of phages (ensuring only lytic 
phages are used in therapy), the purifica-
tion of phage preparations (including the 
removal of endotoxin), and the selection 
of appropriate phages for patients’ unique 
infections. If the FDA were to modernize its 
current stance on phage therapy, scientific 
certainties, not regulatory uncertainties, 
could determine the future of this prom-
ising treatment.
are traditionally employed (Bull et al., 
2002), new and interdisciplinary think-
ing involving bioinformaticists, health 
care professionals, and phage researchers, 
among others, would be required to make 
phage therapy practicable on a large-scale.
Skeptics also argue that phage therapy 
has not proven its mettle in rigorous, large-
scale trials. While it is true that many phage 
therapy studies did not follow Western pro-
tocols, the overall body of evidence sug-
gesting phage therapy’s efficacy, when used 
appropriately, is significant. Phage therapy 
has been extremely effective at treating a 
number of bacterial infections in controlled 
animal studies (Williams Smith et al., 1987; 
Biswas et al., 2002; Hawkins et al., 2010). The 
documented successes of phage therapy in 
Eastern Europe should be taken with a grain 
of salt, if insufficient by Western standards, 
but not entirely discounted. Most impor-
tantly, large-scale, well-controlled studies 
attesting to phage therapy’s effectiveness do 
indeed exist. In 1963, health authorities in 
Tbilisi, Georgia enlisted more than 30,000 
children in a blind study and reported that 
incidences of dysentery were significantly 
lower amongst those who prophylactically 
received a weekly phage pill (1.8 cases per 
1000) rather than a placebo (6.7 cases per 
1000; Sulakvelidze et al., 2001). In a 1983 
study involving several hundred patients 
with suppurative bacterial infections, 
most of which were drug-resistant, phage 
therapy achieved a 92.4% overall success 
rate (Slopek et al., 1987). Most recently, in 
2009, a double-blind Phase II clinical study 
showed phages to be safe and effective at 
treating chronic drug-resistant ear infec-
tions (Wright et al., 2009). These studies and 
many others (Merril et al., 2003; Kropinksi, 
2006; Abedon et al., 2011) hint at a prom-
ising future for phage therapy in Western 
medicine.
Of course, before that future can be fully 
realized, additional research will be needed, 
as discussed briefly above. But in order to 
make that research investment worthwhile, 
especially (but not exclusively) for the 
private sector, and in order to ultimately 
incorporate phage therapy into a larger 
antibacterial arsenal, a regulatory frame-
work must exist that allows phages to be 
utilized to their maximum potential.
At its best, phage therapy is a form of 
personalized medicine because specific 
phages (usually multiple phages combined 
body’s communities of beneficial bacteria. 
In this light, phage therapy represents a 
kind of biomedical “smart bomb,” affect-
ing only a specific target and minimizing 
collateral damage. Indeed, side effects from 
phages in human studies involving both sick 
(Rhoads et al., 2009) and healthy (Bruttin 
and Brussow, 2005) individuals have been 
extremely rare.
Moreover, although bacteria can become 
resistant to phages, phage-resistance is not 
nearly as worrisome as drug-resistance. 
Like bacteria but unlike antibiotics, phages 
mutate and therefore can evolve to counter 
phage-resistant bacteria (Matsuzaki et al., 
2005). Because phages attack bacteria by 
attaching to receptors on the bacterial 
cell surface that are often virulence fac-
tors, phage-resistant mutants (which lack 
these receptors) are often less pathogenic 
than phage-susceptible bacteria (Inal, 
2003). Further, the development of phage-
resistance can be forestalled altogether if 
phages are used in cocktails (preparations 
containing multiple types of phages) and/
or in conjunction with antibiotics. In fact, 
phage therapy and antibiotic therapy, when 
co-applied, are synergistic (Kutateladze and 
Adamia, 2010).
Despite the attractions of phage ther-
apy, scientific and logistical challenges 
remain. Wild-type phage particles are 
rapidly eliminated by the body’s reticu-
loendothelial (mononuclear phagocyte) 
system, so in order to enhance phages’ 
circulatory time and improve the efficacy 
of treatment, long-circulating mutants 
(Merril et al., 1996) must be selected, or 
wild-type virions must be shielded with 
a non-immunogenic polymer such as 
polyethylene glycol (Kim et al., 2008). An 
improved understanding of phages’ in 
vivo pharmacokinetics, including relevant 
inundation and proliferation thresholds, 
would also increase phages’ therapeutic 
value (Cairns et al., 2009). The obstacles 
to phage therapy are not purely scientific: 
manufacturing, production, and distribu-
tion concerns relating to the scalability of 
phage therapy have also been discussed (Lu 
and Koeris, 2011). More broadly, for phage 
therapy to be useful in clinical settings, a 
patient’s specific etiological agent would 
need to be rapidly identified and matched 
to the relevant phage(s) in a comprehen-
sive pre-existing database. Because this sce-
nario is inconsistent with how  antibiotics 
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Phage therapy holds tremendous 
potential as a powerful way to combat 
 increasingly dangerous bacterial infections. 
Even as researchers continue to explore the 
science behind phage therapy, it remains 
unclear if phage therapy will indeed save 
lives on a significant scale or if it will ulti-
mately fail to fulfill its promise. One thing 
seems clear, though: if phage therapy is to 
move out of the twentieth century and into 
the twenty-first, so too must the regulatory 
models that govern it.
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